NASDAQ:RVMD

Revolution Medicines (RVMD) Stock Forecast, Price & News

$30.00

-0.48 (-1.57%)

(As of 09/22/2023 ET)

Compare

Today's Range: $29.60
▼
$30.48
50-Day Range: $25.17
▼
$35.05
52-Week Range: $17.39
▼
$35.50

Volume: 1.82 million shs
Average Volume: 1.11 million shs
Market Capitalization: $3.28 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $35.57

Revolution Medicines MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 18.6% Upside
$35.57 Price Target
Short Interest: Bearish
11.91% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.81
Upright™ Environmental Score
News Sentiment: -0.31
Based on 10 Articles This Week
Insider Trading: Selling Shares
$3.68 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($3.46) to ($3.37) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.55 out of 5 stars

Medical Sector

894th out of 968 stocks

Biological Products, Except Diagnostic Industry

146th out of 160 stocks

2.4

Analyst's Opinion

Consensus Rating
Revolution Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $35.57, Revolution Medicines has a forecasted upside of 18.6% from its current price of $30.00.
Amount of Analyst Coverage
Revolution Medicines has only been the subject of 4 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
11.91% of the outstanding shares of Revolution Medicines have been sold short.
Short Interest Ratio / Days to Cover
Revolution Medicines has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
Change versus previous month
Short interest in Revolution Medicines has recently increased by 8.51%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Revolution Medicines does not currently pay a dividend.
Dividend Growth
Revolution Medicines does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Revolution Medicines has received a 74.67% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Revolution Medicines is -0.81.

1.5

News and Social Media Coverage

News Sentiment
Revolution Medicines has a news sentiment score of -0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Revolution Medicines this week, compared to 2 articles on an average week.
Search Interest
4 people have searched for RVMD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Revolution Medicines insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,683,512.00 in company stock.
Percentage Held by Insiders
Only 8.50% of the stock of Revolution Medicines is held by insiders.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Revolution Medicines are expected to grow in the coming year, from ($3.46) to ($3.37) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Revolution Medicines is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Revolution Medicines is -9.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Revolution Medicines has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a tri-complex inhibitor of KRASG12C(ON) and KRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

RVMD Price History

30 days | 90 days | 365 days | Advanced Chart

RVMD Stock News Headlines

September 21, 2023 | markets.businessinsider.com

Stifel Maintains Buy Rating for Revolution Medicines: Here's What You Need To Know

September 20, 2023 | finance.yahoo.com

Insider Sell: COO Margaret Horn Sells 7,514 Shares of Revolution Medicines Inc (RVMD)

September 22, 2023 | Stansberry Research (Ad)

U.S. "Shadow Banks" About to Blow up again?

Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.

September 19, 2023 | finance.yahoo.com

Revolution Medicines Doses First Patient in Phase 1/1b Clinical Trial of RMC-9805, an Oral, Covalent, Mutant-Selective KRASG12D(ON) Inhibitor

September 15, 2023 | americanbankingnews.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Rating of "Moderate Buy" by Brokerages

August 17, 2023 | finance.yahoo.com

Revolution Medicines Announces Publication Describing Molecular Basis of Tri-Complex Inhibitors Targeting Oncogenic RAS(ON) Proteins

August 9, 2023 | finance.yahoo.com

Industry Analysts Just Made A Sizeable Upgrade To Their Revolution Medicines, Inc. (NASDAQ:RVMD) Revenue Forecasts

August 9, 2023 | finanznachrichten.de

Revolution Medicines, Inc.: Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress

September 22, 2023 | Stansberry Research (Ad)

U.S. "Shadow Banks" About to Blow up again?

Analyst who called Lehman crash says our biggest calamities (1907, 1929, 2007, etc) all start in the same spot--and it’s about to happen again. More here.

August 9, 2023 | msn.com

Needham Maintains Revolution Medicines (RVMD) Buy Recommendation

August 5, 2023 | benzinga.com

Lifshitz Law PLLC Announces Investigations of EQRX, RVMD, NEWR, and RETA

August 3, 2023 | finance.yahoo.com

Revolution Medicines to Report Financial Results for Second Quarter 2023 After Market Close on August 8, 2023

August 1, 2023 | msn.com

Revolution Medicines to acquire EQRx in deal that will add $1 billion in cash to its balance sheet to fund R&D

August 1, 2023 | markets.businessinsider.com

Revolution Medicines To Acquire EQRx In All-Stock Transaction To Gain Over $1B In Additional Capital

August 1, 2023 | businesswire.com

RVMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Revolution Medicines, Inc. Is Fair to Shareholders

July 11, 2023 | seekingalpha.com

Revolution Medicines: Early-Stage Firm Whose High Valuation I Cannot Explain

July 6, 2023 | finance.yahoo.com

Revolution Medicines Insider Ups Holding During Year

June 30, 2023 | fool.com

Revolution Medicines (NASDAQ: RVMD)

June 9, 2023 | finance.yahoo.com

We're Not Very Worried About Revolution Medicines' (NASDAQ:RVMD) Cash Burn Rate

May 24, 2023 | finance.yahoo.com

Revolution Medicines to Participate in TD Cowen 4th Annual Oncology Innovation Summit

May 13, 2023 | finance.yahoo.com

Revolution Medicines, Inc. (NASDAQ:RVMD) Analysts Just Trimmed Their Revenue Forecasts By 25%

May 10, 2023 | finance.yahoo.com

Revolution Medicines First Quarter 2023 Earnings: Beats Expectations

May 9, 2023 | finanznachrichten.de

Revolution Medicines, Inc.: Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress

May 9, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Revolution Medicines

May 9, 2023 | finance.yahoo.com

Q1 2023 Revolution Medicines Inc Earnings Call

May 8, 2023 | seekingalpha.com

Revolution Medicines, Inc. (RVMD) Q1 2023 Earnings Call Transcript

May 8, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Xencor (XNCR) and Revolution Medicines (RVMD)

See More Headlines

Receive RVMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revolution Medicines and its competitors with MarketBeat's FREE daily newsletter.

RVMD Company Calendar

Last Earnings: 8/08/2023
Today: 9/22/2023
Next Earnings (Estimated): 11/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVMD
CUSIP: N/A
CIK: 1628171
Web: www.revmed.com
Phone: 650-481-6801
Fax: N/A
Employees: 292
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $35.57
High Stock Price Forecast: $47.00
Low Stock Price Forecast: $23.00
Forecasted Upside/Downside: +18.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.14)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-248,710,000.00
Net Margins: -1,003.36%
Pretax Margin: -1,004.78%
Return on Equity: -36.46%
Return on Assets: -31.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 11.81
Quick Ratio: 11.81

Sales & Book Value

Annual Sales: $35.38 million
Price / Sales: 92.69
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $7.72 per share
Price / Book: 3.89

Miscellaneous

Outstanding Shares: 109,170,000
Free Float: 99,891,000
Market Cap: $3.28 billion
Optionable: Not Optionable
Beta: 1.36

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Mark A. Goldsmith Ph.D. (Age 61)
CEO, Pres & Chairman
Comp: $1.05M

Mr. Jack Anders (Age 46)
Chief Financial Officer
Comp: $544.8k

Ms. Margaret A. Horn J.D. (Age 60)
Chief Operating Officer
Comp: $775.6k

Dr. Stephen M. Kelsey FRC Path. (Age 62)
FRCP, M.D., Pres of R&D
Comp: $779k

Ms. Xiaolin Wang (Age 52)
Exec. VP of Clinical Devel.
Comp: $604.1k

Dr. Martin D. Burke M.D.
Ph.D., Co-Founder & Chairman of Scientific Advisory Board

Dr. Michael A. Fischbach Ph.D. (Age 42)
Academic Co-Founder & Member of Scientific Advisory Board

Dr. Kevan M. Shokat Ph.D.
Academic Co-Founder & Member of Scientific Advisory Board

Mr. Walter Reiher Ph.D.
Chief Information Officer

Ms. Jan Smith Ph.D.
Chief Scientific Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVMD Stock - Frequently Asked Questions

Should I buy or sell Revolution Medicines stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Revolution Medicines in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RVMD shares.
View RVMD analyst ratings or view top-rated stocks.
What is Revolution Medicines' stock price forecast for 2023?: 7 brokerages have issued 12-month price objectives for Revolution Medicines' stock. Their RVMD share price forecasts range from $23.00 to $47.00. On average, they anticipate the company's stock price to reach $35.57 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts price targets for RVMD or view top-rated stocks among Wall Street analysts.
How have RVMD shares performed in 2023?: Revolution Medicines' stock was trading at $23.82 on January 1st, 2023. Since then, RVMD stock has increased by 26.1% and is now trading at $30.04.
View the best growth stocks for 2023 here.
When is Revolution Medicines' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023.
View our RVMD earnings forecast.
How were Revolution Medicines' earnings last quarter?: Revolution Medicines, Inc. (NASDAQ:RVMD) released its quarterly earnings data on Tuesday, August, 8th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.10. The firm had revenue of $3.82 million for the quarter, compared to analyst estimates of $1.56 million. Revolution Medicines had a negative net margin of 1,003.36% and a negative trailing twelve-month return on equity of 36.46%. The business's revenue for the quarter was down 58.1% compared to the same quarter last year. During the same quarter last year, the company earned ($0.82) earnings per share.
What ETFs hold Revolution Medicines' stock?: ETFs with the largest weight of Revolution Medicines (NASDAQ:RVMD) stock in their portfolio include Range Cancer Therapeutics ETF (CNCR), SPDR S&P Biotech ETF (XBI), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Direxion Daily S&P Biotech Bull 3x Shares (LABU) and Principal Healthcare Innovators ETF (BTEC).Invesco Nasdaq Biotechnology ETF (IBBQ).
What other stocks do shareholders of Revolution Medicines own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Revolution Medicines investors own include Alector (ALEC), Editas Medicine (EDIT), Homology Medicines (FIXX), Gossamer Bio (GOSS), Livongo Health (LVGO), Sorrento Therapeutics (SRNE), Black Diamond Therapeutics (BDTX), Beam Therapeutics (BEAM), CrowdStrike (CRWD) and Precision BioSciences (DTIL).

When did Revolution Medicines IPO?: (RVMD) raised $150 million in an IPO on Thursday, February 13th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen, SVB Leerink and Guggenheim Securities served as the underwriters for the IPO.
What is Revolution Medicines' stock symbol?: Revolution Medicines trades on the NASDAQ under the ticker symbol "RVMD."
Who are Revolution Medicines' major shareholders?: Revolution Medicines' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.56%), BVF Inc. IL (5.73%), Bellevue Group AG (4.35%), State Street Corp (4.35%), JPMorgan Chase & Co. (3.63%) and Woodline Partners LP (3.45%). Insiders that own company stock include Anthony W Boor, Barbara Weber, Elizabeth M Anderson, Jack Anders, Jeanna Steele, Jeff Cislini, Lorence H Kim, Margaret A Horn, Mark A Goldsmith, Peter Svennilson, Rock Ventures Ii LP Third, Rock Ventures Iii LP Third, Stephen Michael Kelsey, Thilo Schroeder, Vincent A Miller and Xiaolin Wang.
View institutional ownership trends.
How do I buy shares of Revolution Medicines?: Shares of RVMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Revolution Medicines' stock price today?: One share of RVMD stock can currently be purchased for approximately $30.04.
How much money does Revolution Medicines make?: Revolution Medicines (NASDAQ:RVMD) has a market capitalization of $3.28 billion and generates $35.38 million in revenue each year. The company earns $-248,710,000.00 in net income (profit) each year or ($3.14) on an earnings per share basis.
How many employees does Revolution Medicines have?: The company employs 292 workers across the globe.
How can I contact Revolution Medicines?: Revolution Medicines' mailing address is 700 Saginaw Drive, Redwood City CA, 94063. The official website for the company is www.revmed.com. The company can be reached via phone at 650-481-6801 or via email at ir@revmed.com.

This page (NASDAQ:RVMD) was last updated on 9/22/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial